Compare RVYL & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | EVGN |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Agricultural Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 10.9M |
| IPO Year | N/A | N/A |
| Metric | RVYL | EVGN |
|---|---|---|
| Price | $0.34 | $1.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | ★ 7.5M | 51.3K |
| Earning Date | 11-14-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,858,000.00 | $8,016,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $297.49 | $12.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 29.50 | 7.19 |
| 52 Week Low | $0.25 | $0.95 |
| 52 Week High | $2.33 | $2.42 |
| Indicator | RVYL | EVGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 41.97 |
| Support Level | $0.32 | $1.03 |
| Resistance Level | $0.37 | $1.14 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 66.35 | 31.12 |
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.